Biosimilar/Generic Injectable Pens Market Size is valued at XX Million in 2024 and is predicted to reach XX Million by the year 2034 at an XX% CAGR during the forecast period for 2025-2034.
Biosimilar is defined as a type of biological product that is approved by respective regulatory bodies because of its clinical similarity to already approved biological products. This is relatively cheaper than biologics. With an increase in complex molecules or biologics coming into the market, drug developers continue to look for innovative technology that can simplify delivery needs. Introduction to injectable pens addresses the problem of complex drug delivery regimens. They are easy to handle, convenient, and repeatedly deliver accurate dosages.
Injectable pens are generally used for the administration of insulin, growth hormone, and other medication. Many biologic therapies are currently approved for the treatment of various diseases are available in injectable pen form. Certain biologics had lost patents along with many biologics are going to lose the patent in coming years, thus biosimilar injectable pens market is expected to gain popularity in the coming year. In addition to it, the growing incidence and prevalence of chronic diseases like, diabetes, arthritis, etc. that requires daily dosing (self-administration) expected to increase the demand for injectable pens in coming years. However, preference for alternative drug delivery modes and stringent regulatory hurdles for the approval of biosimilars are the factor restrains the growth of the market.
The biosimilar injectable pens market is segregated in terms of drugs used in pens. product type, dosage, therapies, distribution channel and region. On the basis of product type the market is classified into disposable biosimilar injectable pens and reusable biosimilar injectable pens. The disposable injectable pens segment is expected to expand at significant CAGR during the forecast period due to the low possibility of infection and ease of use. In terms of dosage the market is segregated into fixed-dose and variable dose. In terms of therapies the global biosimilar injectable pens market is segmented into Diabetes, Oncology, Autoimmune Diseases, Growth Hormone Deficiency, Other (e.g., Osteoporosis). The diabetes segment expected to hold significant share of the market due to the presence of a huge diabetic patient pool and the growing adoption of injectable pens. The distribution channel cosists of Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Direct Sales (B2B).
On the basis of geography, the global biosimilar injectable pens market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In terms of revenue, North America followed by Europe is major contributor to the global biosimilar injectable pens market. This is because the rise in incidence and prevalence of various diseases, presence of major players, patent expiry of leading biologics, entry of biosimilars, and strong ongoing clinical pipeline propels the growth of the market in the region. Asia Pacific is third promising revenue contributor which is expected to grow at rapid pace in an upcoming year. The population in the countries such as India and China are becoming wealthier and demanding better treatment options. Furthermore, shifting healthcare infrastructure and demographic trends contribute to the growth of the region. Emerging and huge population base countries such as China and India offer tremendous market opportunities to the key market players operating in global biosimilar injectable pens market.
Biosimilar and Generic Drug Companies
Injectable Pen Device Companies
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD XX Million |
|
Revenue Forecast In 2034 |
USD XX Million |
|
Growth Rate CAGR |
CAGR of XX % from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Million, Volume (Unit), and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drugs used in pens, By Type, By Dosage, By Therapies, By Distribution channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
Ypsomed, SHL Group, Copernicus, Owen Mumford, Haselmeier, Jiangsu Delfu medical device Co.,Ltd, Emperra GmbH, Digital Medics Ptd Ltd., and Others |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Biosimilar/Generic Injectable Pens Market Snapshot
Chapter 4. Global Biosimilar/Generic Injectable Pens Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental OpportNo.Of. Unitsy Analysis (US$ MN), 2025-2034
4.8. Global Biosimilar/Generic Injectable Pens Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on BIOSIMILAR/GENERIC INJECTABLE PENS MARKET Industry Trends
Chapter 5. Biosimilar/Generic Injectable Pens Market Segmentation 1: By Drug Used in Pens, Estimates & Trend Analysis
5.1. Market Share by Drug Used in Pens, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Volume (No.Of. Units)) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drug Used in Pens:
5.2.1. Biosimilar
5.2.2. Generics
Chapter 6. Biosimilar/Generic Injectable Pens Market Segmentation 2: By Type, Estimates & Trend Analysis
6.1. Market Share by Type, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Volume (No.Of. Units)) & Forecasts and Trend Analyses, 2021 to 2034 for the following Type:
6.2.1. Disposable biosimilar Injectable Pens
6.2.2. Reusable biosimilar Injectable Pens
Chapter 7. Biosimilar/Generic Injectable Pens Market Segmentation 3: By Distribution Channel, Estimates & Trend Analysis
7.1. Market Share by Distribution Channel, 2024 & 2034
7.2. Market Size (Value (US$ Mn) & Volume (No.Of. Units)) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channel:
7.2.1. Hospital Pharmacies
7.2.2. Retail Pharmacies
7.2.3. Online Pharmacies
7.2.4. Direct Sales (B2B)
Chapter 8. Biosimilar/Generic Injectable Pens Market Segmentation 4: By Dosage, Estimates & Trend Analysis
8.1. Market Share by Dosage, 2024 & 2034
8.2. Market Size (Value (US$ Mn) & Volume (No.Of. Units)) & Forecasts and Trend Analyses, 2021 to 2034 for the following Dosage:
8.2.1. Fixed Dose
8.2.2. Variable Dose
Chapter 9. Biosimilar/Generic Injectable Pens Market Segmentation 5: By Therapies, Estimates & Trend Analysis
9.1. Market Share by Therapies, 2024 & 2034
9.2. Market Size (Value (US$ Mn) & Volume (No.Of. Units)) & Forecasts and Trend Analyses, 2021 to 2034 for the following Therapies:
9.2.1. Diabetes
9.2.2. Oncology
9.2.3. Autoimmune Diseases
9.2.4. Growth Hormone Deficiency
9.2.5. Other (e.g., Osteoporosis)
Chapter 10. Biosimilar/Generic Injectable Pens Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Biosimilar/Generic Injectable Pens Market, Regional Snapshot 2024 & 2034
10.2. North America
10.2.1. North America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Country, 2021-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Drug Used in Pens, 2021-2034
10.2.3. North America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Type, 2021-2034
10.2.4. North America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Distribution Channel, 2021-2034
10.2.5. North America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Dosage, 2021-2034
10.2.6. North America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Therapies, 2021-2034
10.3. Europe
10.3.1. Europe Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Country, 2021-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Drug Used in Pens, 2021-2034
10.3.3. Europe Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Type, 2021-2034
10.3.4. Europe Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Distribution Channel, 2021-2034
10.3.5. Europe Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Dosage, 2021-2034
10.3.6. Europe Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Therapies, 2021-2034
10.4. Asia Pacific
10.4.1. Asia Pacific Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Country, 2021-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Drug Used in Pens, 2021-2034
10.4.3. Asia Pacific Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Type, 2021-2034
10.4.4. Asia Pacific Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Distribution Channel, 2021-2034
10.4.5. Asia Pacific Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts By Dosage, 2021-2034
10.4.6. Asia Pacific Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Therapies, 2021-2034
10.5. Latin America
10.5.1. Latin America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Country, 2021-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Drug Used in Pens, 2021-2034
10.5.3. Latin America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Type, 2021-2034
10.5.4. Latin America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Distribution Channel, 2021-2034
10.5.5. Latin America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Dosage, 2021-2034
10.5.6. Latin America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Therapies, 2021-2034
10.6. Middle East & Africa
10.6.1. Middle East & Africa Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by country, 2021-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Drug Used in Pens, 2021-2034
10.6.3. Middle East & Africa Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Type, 2021-2034
10.6.4. Middle East & Africa Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Distribution Channel, 2021-2034
10.6.5. Middle East & Africa Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Dosage, 2021-2034
10.6.6. Middle East & Africa Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Therapies, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
Biosimilar and Generic Drug Companies
11.2.1. Sandoz International GmbH (Novartis)
11.2.1.1. Business Overview
11.2.1.2. Key Product/Service
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Pfizer Inc. (via Hospira)
11.2.3. Amgen Inc.
11.2.4. Teva Pharmaceutical Industries Ltd.
11.2.5. Biocon Ltd.
11.2.6. Celltrion Healthcare Co., Ltd.
11.2.7. Reddy’s Laboratories Ltd.
11.2.8. Eli Lilly and Company
11.2.9. Civica Rx
11.2.10. Fresenius Kabi AG
11.2.11. Other prominent players
Injectable Pen Device Companies
11.2.12. Ypsomed Holding AG
11.2.13. SHL Group (SHL Medical AG)
11.2.14. Owen Mumford Ltd.
11.2.15. Haselmeier
11.2.16. Gerresheimer AG
11.2.17. Phillips Medisize
11.2.18. DCA Design (for Sanofi)
11.2.19. Jiangsu Delfu Medical Device Co., Ltd.
11.2.20. Emperra GmbH
11.2.21. Companion Medical, Inc.
11.2.22. Digital Medics Pty Ltd
11.2.23. Copernicus
11.2.24. Diamesco Co., Ltd.
11.2.25. Other prominent players
Global Biosimilar Injectable Pens Market Outlook (Value (US$ Mn) & Volume (no. of units), By Drug Used in Pens
Global Biosimilar Injectable Pens Market Outlook (Value (US$ Mn) & Volume (no. of units), By Type
Global Biosimilar Injectable Pens Market Outlook (Value (US$ Mn) & Volume (no. of units), By Dosage
Global Biosimilar Injectable Pens Market Outlook (Value (US$ Mn) & Volume (no. of units), By Therapies
Global Biosimilar Injectable Pens Market Outlook (Value (US$ Mn) & Volume (no. of units), By Distribution Channel
Global Biosimilar Injectable Pens Market Outlook (Value (US$ Mn) & Volume (no. of units), By Region
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
